RESUMEN
Typhoid fever, an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi), is endemic in many low- and middle-income countries (1). In 2015, an estimated 11-21 million typhoid fever cases and 148,000-161,000 associated deaths occurred worldwide (2). Effective prevention strategies include improved access to and use of infrastructure supporting safe water, sanitation, and hygiene (WASH); health education; and vaccination (1). The World Health Organization (WHO) recommends programmatic use of typhoid conjugate vaccines for typhoid fever control and prioritization of vaccine introduction in countries with the highest typhoid fever incidence or high prevalence of antimicrobial-resistant S. Typhi (1). This report describes typhoid fever surveillance, incidence estimates, and the status of typhoid conjugate vaccine introduction during 2018-2022. Because routine surveillance for typhoid fever has low sensitivity, population-based studies have guided estimates of case counts and incidence in 10 countries since 2016 (3-6). In 2019, an updated modeling study estimated that 9.2 million (95% CI = 5.9-14.1) typhoid fever cases and 110,000 (95% CI = 53,000-191,000) deaths occurred worldwide, with the highest estimated incidence in the WHO South-East Asian (306 cases per 100,000 persons), Eastern Mediterranean (187), and African (111) regions (7). Since 2018, five countries (Liberia, Nepal, Pakistan, Samoa [based on self-assessment], and Zimbabwe) with estimated high typhoid fever incidence (≥100 cases per 100,000 population per year) (8), high antimicrobial resistance prevalence, or recent outbreaks introduced typhoid conjugate vaccines into their routine immunization programs (2). To guide vaccine introduction decisions, countries should consider all available information, including surveillance of laboratory-confirmed cases, population-based and modeling studies, and outbreak reports. Establishing and strengthening typhoid fever surveillance will be important to measure vaccine impact.
Asunto(s)
Antiinfecciosos , Fiebre Tifoidea , Vacunas Tifoides-Paratifoides , Humanos , Fiebre Tifoidea/epidemiología , Fiebre Tifoidea/prevención & control , Vacunas Conjugadas , IncidenciaRESUMEN
SUMMARY: During 2007, 49 states and Puerto Rico reported 7,258 cases of rabies in animals and 1 case in a human to the CDC, representing a 4.6% increase from the 6,940 cases in animals and 3 cases in humans reported in 2006. Approximately 93% of the cases were in wildlife, and 7% were in domestic animals. Relative contributions by the major animal groups were as follows: 2,659 raccoons (36.6%), 1,973 bats (27.2%), 1,478 skunks (20.4%), 489 foxes (6.7%), 274 cats (3.8%), 93 dogs (1.3%), and 57 cattle (0.8%). Compared with numbers of reported cases in 2006, cases in 2007 increased among dogs, bats, foxes, and skunks while decreases were reported among cattle, cats, and skunks. Increases in numbers of rabid raccoons during 2007 were reported by 11 of the 20 eastern states where raccoon rabies was enzootic, and reported cases increased by 1.7% overall, compared with 2006. On a national level, the number of rabies cases in skunks during 2007 decreased by 1.1% from the number reported in 2006. Texas reported the greatest number (n = 362) of rabid skunks and the greatest overall state total of animal rabies cases (969). No cases of rabies associated with the dog/coyote rabies virus variant were reported. The United States remains free of dog-to-dog transmission of canine rabies virus variants. The total number of cases of rabies reported nationally in foxes increased 14.5%, compared with 2006. Increases in the number of reported rabid foxes were attributable to greater numbers of foxes reported with the Arctic fox rabies virus variant in Alaska, the Texas gray fox rabies virus variant in Texas, and the raccoon rabies virus variant in Virginia. The 1,973 cases of rabies reported in bats represented a 16.6% increase over numbers reported in 2006. Cases of rabies in dogs and in sheep and goats increased 17.7% and 18.2%, respectively, whereas cases reported in cattle, cats, and horses and mules decreased 30.5%, 13.8%, and 20.8%, respectively. In Puerto Rico, reported cases of rabies in mongooses decreased 51.5%, and rabies in domestic animals, presumably attributable to spillover infection from mongooses, increased 25%. One human rabies case was reported from Minnesota during 2007. Although typing of the rabies virus variant in this case was not possible, an investigation of this case indicated a bat as the most likely source of exposure.
Asunto(s)
Animales Domésticos , Animales Salvajes , Centers for Disease Control and Prevention, U.S./estadística & datos numéricos , Salud Pública , Rabia/veterinaria , Vigilancia de Guardia/veterinaria , Animales , Enfermedades de los Gatos/epidemiología , Enfermedades de los Gatos/transmisión , Enfermedades de los Gatos/virología , Gatos , Bovinos , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/transmisión , Enfermedades de los Bovinos/virología , Quirópteros/virología , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/virología , Perros , Equidae/virología , Zorros/virología , Geografía , Humanos , Mephitidae/virología , Prevalencia , Rabia/epidemiología , Rabia/transmisión , Rabia/virología , Vacunas Antirrábicas/administración & dosificación , Mapaches/virología , Estados Unidos/epidemiología , ZoonosisRESUMEN
To better track public health events in areas where the public health system is unable or unwilling to report the event to appropriate public health authorities, agencies can conduct event-based surveillance, which is defined as the organized collection, monitoring, assessment, and interpretation of unstructured information regarding public health events that may represent an acute risk to public health. The US Centers for Disease Control and Prevention's (CDC's) Global Disease Detection Operations Center (GDDOC) was created in 2007 to serve as CDC's platform dedicated to conducting worldwide event-based surveillance, which is now highlighted as part of the "detect" element of the Global Health Security Agenda (GHSA). The GHSA works toward making the world more safe and secure from disease threats through building capacity to better "Prevent, Detect, and Respond" to those threats. The GDDOC monitors approximately 30 to 40 public health events each day. In this article, we describe the top threats to public health monitored during 2012 to 2016: avian influenza, cholera, Ebola virus disease, and the vector-borne diseases yellow fever, chikungunya virus, and Zika virus, with updates to the previously described threats from Middle East respiratory syndrome-coronavirus (MERS-CoV) and poliomyelitis.
Asunto(s)
Enfermedades Transmisibles/epidemiología , Monitoreo Epidemiológico , Animales , Aves , Centers for Disease Control and Prevention, U.S. , Fiebre Chikungunya/epidemiología , Cólera/epidemiología , Infecciones por Coronavirus/epidemiología , Brotes de Enfermedades , Salud Global , Fiebre Hemorrágica Ebola/epidemiología , Humanos , Gripe Aviar/epidemiología , Poliomielitis/epidemiología , Estados Unidos , Fiebre Amarilla/epidemiología , Infección por el Virus Zika/epidemiologíaRESUMEN
Disease outbreaks of international public health importance continue to occur regularly; detecting and tracking significant new public health threats in countries that cannot or might not report such events to the global health community is a challenge. The Centers for Disease Control and Prevention's (CDC) Global Disease Detection (GDD) Operations Center, established in early 2007, monitors infectious and non-infectious public health events to identify new or unexplained global public health threats and better position CDC to respond, if public health assistance is requested or required. At any one time, the GDD Operations Center actively monitors approximately 30-40 such public health threats; here we provide our perspective on five of the top global infectious disease threats that we were watching in 2012: 1 avian influenza A (H5N1), 2 cholera, 3 wild poliovirus, 4 enterovirus-71, and 5 extensively drug-resistant tuberculosis11Current address: Division of Integrated Biosurveillance, Armed Forces Health Surveillance Center, US Department of Defense, Silver Spring, MD, USA.
Asunto(s)
Biovigilancia , Control de Enfermedades Transmisibles , Brotes de Enfermedades/prevención & control , Salud Global , Animales , Aves , Centers for Disease Control and Prevention, U.S. , Cólera/epidemiología , Cólera/prevención & control , Farmacorresistencia Bacteriana Múltiple , Enterovirus Humano A , Infecciones por Enterovirus/epidemiología , Infecciones por Enterovirus/prevención & control , Humanos , Subtipo H5N1 del Virus de la Influenza A , Gripe Aviar/epidemiología , Gripe Aviar/prevención & control , Poliomielitis/epidemiología , Poliomielitis/prevención & control , Poliovirus , Tuberculosis/epidemiología , Tuberculosis/prevención & control , Estados UnidosRESUMEN
BACKGROUND: The United States of America (USA) does not have a national reporting system for rabies post-exposure prophylaxis (PEP). We describe the epidemiology of PEP in the USA so recommendations can be made during a PEP shortage. METHODS: A two-part questionnaire designed to evaluate PEP distribution practices and estimate PEP use was administered to state health department representatives. RESULTS: Seventy-five percent of participants responded that no public health guidance was needed to make a recommendation for PEP. The annual national average PEP use is 23,415 courses of PEP (range: 10,645-35,845). CONCLUSION: PEP is loosely monitored and a precise estimate of PEP use is unknown. Improved national surveillance for PEP is needed.